25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Starpharma Holdings Ltd
Buy, Hold or Sell?

Let's analyze Starpharma together

I guess you are interested in Starpharma Holdings Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Starpharma Holdings Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Starpharma Holdings Ltd

I send you an email if I find something interesting about Starpharma Holdings Ltd.

1. Quick Overview

1.1. Quick analysis of Starpharma (30 sec.)










1.2. What can you expect buying and holding a share of Starpharma? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
30.0%

What is your share worth?

Current worth
A$0.07
Expected worth in 1 year
A$0.00
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
A$-0.06
Return On Investment
-65.5%

For what price can you sell your share?

Current Price per Share
A$0.10
Expected price per share
A$0.086 - A$0.1
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Starpharma (5 min.)




Live pricePrice per Share (EOD)
A$0.10
Intrinsic Value Per Share
A$-0.21 - A$0.05
Total Value Per Share
A$-0.14 - A$0.11

2.2. Growth of Starpharma (5 min.)




Is Starpharma growing?

Current yearPrevious yearGrowGrow %
How rich?$18.5m$22.9m-$4.4m-23.8%

How much money is Starpharma making?

Current yearPrevious yearGrowGrow %
Making money-$5.3m-$10.2m$4.9m91.5%
Net Profit Margin-98.5%-532.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Starpharma (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#560 / 958

Most Revenue
#334 / 958

Most Profit
#447 / 958

Most Efficient
#450 / 958
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Starpharma?

Welcome investor! Starpharma's management wants to use your money to grow the business. In return you get a share of Starpharma.

First you should know what it really means to hold a share of Starpharma. And how you can make/lose money.

Speculation

The Price per Share of Starpharma is A$0.098. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Starpharma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Starpharma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.07. Based on the TTM, the Book Value Change Per Share is A$-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Starpharma.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.01-13.1%-0.01-13.1%-0.02-25.2%-0.02-23.9%-0.02-21.3%
Usd Book Value Change Per Share-0.01-10.8%-0.01-10.8%-0.02-21.9%0.00-4.6%0.00-0.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.0114.9%0.0215.8%
Usd Total Gains Per Share-0.01-10.8%-0.01-10.8%-0.02-21.9%0.0110.3%0.0115.0%
Usd Price Per Share0.06-0.06-0.20-0.50-0.55-
Price to Earnings Ratio-4.86--4.86--8.27--19.17--17.38-
Price-to-Total Gains Ratio-5.92--5.92--9.53--14.40--14.25-
Price to Book Ratio1.41-1.41-3.72-7.30-7.76-
Price-to-Total Gains Ratio-5.92--5.92--9.53--14.40--14.25-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0645428
Number of shares15493
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.010.00
Usd Total Gains Per Share-0.010.01
Gains per Quarter (15493 shares)-163.78156.58
Gains per Year (15493 shares)-655.10626.33
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-655-665906-279616
20-1310-13201811-5591242
30-1965-19752717-8381868
40-2620-26303622-11172494
50-3276-32854528-13963120
60-3931-39405434-16763746
70-4586-45956339-19554372
80-5241-52507245-22344998
90-5896-59058150-25135624
100-6551-65609056-27936250

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%1.09.00.010.0%2.023.00.08.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%4.06.00.040.0%11.014.00.044.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%1.00.04.020.0%3.00.07.030.0%3.00.022.012.0%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%4.06.00.040.0%11.014.00.044.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Starpharma Holdings Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.016-0.0160%-0.033+103%-0.007-57%-0.001-93%
Book Value Per Share--0.0670.0670%0.083-19%0.098-31%0.107-37%
Current Ratio--4.9414.9410%3.256+52%5.277-6%6.728-27%
Debt To Asset Ratio--0.2360.2360%0.332-29%0.2370%0.181+31%
Debt To Equity Ratio--0.3090.3090%0.496-38%0.319-3%0.231+34%
Dividend Per Share----0%-0%0.022-100%0.023-100%
Eps---0.020-0.0200%-0.037+92%-0.036+82%-0.032+62%
Free Cash Flow Per Share---0.017-0.0170%-0.034+100%-0.029+73%-0.032+87%
Free Cash Flow To Equity Per Share---0.028-0.0280%-0.036+26%-0.008-70%-0.009-70%
Gross Profit Margin--1.4491.4490%1.208+20%1.239+17%1.176+23%
Intrinsic Value_10Y_max--0.046--------
Intrinsic Value_10Y_min---0.206--------
Intrinsic Value_1Y_max---0.021--------
Intrinsic Value_1Y_min---0.029--------
Intrinsic Value_3Y_max---0.044--------
Intrinsic Value_3Y_min---0.081--------
Intrinsic Value_5Y_max---0.043--------
Intrinsic Value_5Y_min---0.125--------
Market Cap40902064.000+3%39649960.00039649960.0000%129384080.000-69%314278104.000-87%350380436.000-89%
Net Profit Margin---0.985-0.9850%-5.321+440%-4.633+370%-5.047+412%
Operating Margin---1.297-1.2970%-8.395+547%-6.858+429%-6.146+374%
Operating Ratio--2.2972.2970%9.395-76%7.858-71%7.160-68%
Pb Ratio1.455+3%1.4101.4100%3.716-62%7.303-81%7.758-82%
Pe Ratio-5.009-3%-4.856-4.8560%-8.274+70%-19.172+295%-17.375+258%
Price Per Share0.098+3%0.0950.0950%0.310-69%0.753-87%0.840-89%
Price To Free Cash Flow Ratio-5.789-3%-5.611-5.6110%-9.141+63%-24.267+332%-27.436+389%
Price To Total Gains Ratio-6.106-3%-5.919-5.9190%-9.529+61%-14.400+143%-14.250+141%
Quick Ratio--4.4584.4580%3.000+49%5.022-11%6.488-31%
Return On Assets---0.222-0.2220%-0.300+35%-0.282+27%-0.289+31%
Return On Equity---0.290-0.2900%-0.449+55%-0.372+28%-0.357+23%
Total Gains Per Share---0.016-0.0160%-0.033+103%0.015-205%0.022-172%
Usd Book Value--18517197.60018517197.6000%22929159.000-19%26996014.000-31%29544005.614-37%
Usd Book Value Change Per Share---0.011-0.0110%-0.021+103%-0.005-57%-0.001-93%
Usd Book Value Per Share--0.0440.0440%0.055-19%0.065-31%0.071-37%
Usd Dividend Per Share----0%-0%0.015-100%0.015-100%
Usd Eps---0.013-0.0130%-0.025+92%-0.023+82%-0.021+62%
Usd Free Cash Flow---4653667.600-4653667.6000%-9321824.400+100%-8057839.280+73%-8703267.280+87%
Usd Free Cash Flow Per Share---0.011-0.0110%-0.022+100%-0.019+73%-0.021+87%
Usd Free Cash Flow To Equity Per Share---0.019-0.0190%-0.023+26%-0.006-70%-0.006-70%
Usd Market Cap26938099.350+3%26113463.65626113463.6560%85212355.088-69%206983559.294-87%230760555.150-89%
Usd Price Per Share0.065+3%0.0630.0630%0.204-69%0.496-87%0.553-89%
Usd Profit---5377469.000-5377469.0000%-10299186.800+92%-9795621.240+82%-10166478.900+89%
Usd Revenue--5459135.4005459135.4000%1935625.400+182%3127164.520+75%2722388.960+101%
Usd Total Gains Per Share---0.011-0.0110%-0.021+103%0.010-205%0.015-172%
 EOD+5 -3MRQTTM+0 -0YOY+26 -85Y+18 -1810Y+16 -20

3.3 Fundamental Score

Let's check the fundamental score of Starpharma Holdings Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.009
Price to Book Ratio (EOD)Between0-11.455
Net Profit Margin (MRQ)Greater than0-0.985
Operating Margin (MRQ)Greater than0-1.297
Quick Ratio (MRQ)Greater than14.458
Current Ratio (MRQ)Greater than14.941
Debt to Asset Ratio (MRQ)Less than10.236
Debt to Equity Ratio (MRQ)Less than10.309
Return on Equity (MRQ)Greater than0.15-0.290
Return on Assets (MRQ)Greater than0.05-0.222
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Starpharma Holdings Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.097
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Starpharma Holdings Ltd

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It is also involved in the development of dendrimer enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; SPL7013 for vaginal gel; and DEP HER2 radiodiagnostic. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

Fundamental data was last updated by Penke on 2024-10-17 00:41:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Starpharma earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • A Net Profit Margin of -98.5% means that $-0.99 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Starpharma Holdings Ltd:

  • The MRQ is -98.5%. The company is making a huge loss. -2
  • The TTM is -98.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-98.5%TTM-98.5%0.0%
TTM-98.5%YOY-532.1%+433.6%
TTM-98.5%5Y-463.3%+364.8%
5Y-463.3%10Y-504.7%+41.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-98.5%-135.5%+37.0%
TTM-98.5%-205.3%+106.8%
YOY-532.1%-207.5%-324.6%
5Y-463.3%-353.5%-109.8%
10Y-504.7%-464.5%-40.2%
4.3.1.2. Return on Assets

Shows how efficient Starpharma is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • -22.2% Return on Assets means that Starpharma generated $-0.22 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Starpharma Holdings Ltd:

  • The MRQ is -22.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -22.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-22.2%TTM-22.2%0.0%
TTM-22.2%YOY-30.0%+7.8%
TTM-22.2%5Y-28.2%+6.0%
5Y-28.2%10Y-28.9%+0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-22.2%-10.9%-11.3%
TTM-22.2%-11.8%-10.4%
YOY-30.0%-11.1%-18.9%
5Y-28.2%-12.7%-15.5%
10Y-28.9%-14.3%-14.6%
4.3.1.3. Return on Equity

Shows how efficient Starpharma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • -29.0% Return on Equity means Starpharma generated $-0.29 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Starpharma Holdings Ltd:

  • The MRQ is -29.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -29.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-29.0%TTM-29.0%0.0%
TTM-29.0%YOY-44.9%+15.9%
TTM-29.0%5Y-37.2%+8.1%
5Y-37.2%10Y-35.7%-1.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.0%-13.7%-15.3%
TTM-29.0%-16.0%-13.0%
YOY-44.9%-13.5%-31.4%
5Y-37.2%-18.5%-18.7%
10Y-35.7%-19.0%-16.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Starpharma Holdings Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Starpharma is operating .

  • Measures how much profit Starpharma makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • An Operating Margin of -129.7% means the company generated $-1.30  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Starpharma Holdings Ltd:

  • The MRQ is -129.7%. The company is operating very inefficient. -2
  • The TTM is -129.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-129.7%TTM-129.7%0.0%
TTM-129.7%YOY-839.5%+709.8%
TTM-129.7%5Y-685.8%+556.2%
5Y-685.8%10Y-614.6%-71.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-129.7%-286.0%+156.3%
TTM-129.7%-313.4%+183.7%
YOY-839.5%-222.8%-616.7%
5Y-685.8%-385.5%-300.3%
10Y-614.6%-494.6%-120.0%
4.3.2.2. Operating Ratio

Measures how efficient Starpharma is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.30 means that the operating costs are $2.30 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 2.297. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.297. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.297TTM2.2970.000
TTM2.297YOY9.395-7.098
TTM2.2975Y7.858-5.562
5Y7.85810Y7.160+0.699
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2972.842-0.545
TTM2.2973.179-0.882
YOY9.3953.300+6.095
5Y7.8584.823+3.035
10Y7.1606.520+0.640
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Starpharma Holdings Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Starpharma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.94 means the company has $4.94 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 4.941. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.941. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.941TTM4.9410.000
TTM4.941YOY3.256+1.685
TTM4.9415Y5.277-0.336
5Y5.27710Y6.728-1.451
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9413.747+1.194
TTM4.9413.923+1.018
YOY3.2564.715-1.459
5Y5.2775.960-0.683
10Y6.7286.291+0.437
4.4.3.2. Quick Ratio

Measures if Starpharma is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • A Quick Ratio of 4.46 means the company can pay off $4.46 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 4.458. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.458. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.458TTM4.4580.000
TTM4.458YOY3.000+1.458
TTM4.4585Y5.022-0.564
5Y5.02210Y6.488-1.466
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.4583.342+1.116
TTM4.4583.522+0.936
YOY3.0004.658-1.658
5Y5.0225.922-0.900
10Y6.4886.478+0.010
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Starpharma Holdings Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Starpharma assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Starpharma to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.24 means that Starpharma assets are financed with 23.6% credit (debt) and the remaining percentage (100% - 23.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 0.236. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.236. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.236TTM0.2360.000
TTM0.236YOY0.332-0.095
TTM0.2365Y0.237-0.001
5Y0.23710Y0.181+0.056
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2360.338-0.102
TTM0.2360.346-0.110
YOY0.3320.308+0.024
5Y0.2370.365-0.128
10Y0.1810.379-0.198
4.5.4.2. Debt to Equity Ratio

Measures if Starpharma is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Starpharma to the Biotechnology industry mean.
  • A Debt to Equity ratio of 30.9% means that company has $0.31 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 0.309. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.309. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.309TTM0.3090.000
TTM0.309YOY0.496-0.187
TTM0.3095Y0.319-0.010
5Y0.31910Y0.231+0.088
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3090.392-0.083
TTM0.3090.439-0.130
YOY0.4960.375+0.121
5Y0.3190.450-0.131
10Y0.2310.488-0.257
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Starpharma generates.

  • Above 15 is considered overpriced but always compare Starpharma to the Biotechnology industry mean.
  • A PE ratio of -4.86 means the investor is paying $-4.86 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Starpharma Holdings Ltd:

  • The EOD is -5.009. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.856. Based on the earnings, the company is expensive. -2
  • The TTM is -4.856. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.009MRQ-4.856-0.153
MRQ-4.856TTM-4.8560.000
TTM-4.856YOY-8.274+3.418
TTM-4.8565Y-19.172+14.316
5Y-19.17210Y-17.375-1.797
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.009-2.326-2.683
MRQ-4.856-2.468-2.388
TTM-4.856-2.987-1.869
YOY-8.274-3.444-4.830
5Y-19.172-5.905-13.267
10Y-17.375-6.278-11.097
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Starpharma Holdings Ltd:

  • The EOD is -5.789. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.611. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.611. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.789MRQ-5.611-0.177
MRQ-5.611TTM-5.6110.000
TTM-5.611YOY-9.141+3.530
TTM-5.6115Y-24.267+18.656
5Y-24.26710Y-27.436+3.168
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.789-3.181-2.608
MRQ-5.611-3.267-2.344
TTM-5.611-3.527-2.084
YOY-9.141-4.590-4.551
5Y-24.267-8.076-16.191
10Y-27.436-8.938-18.498
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Starpharma is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.41 means the investor is paying $1.41 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Starpharma Holdings Ltd:

  • The EOD is 1.455. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.410. Based on the equity, the company is underpriced. +1
  • The TTM is 1.410. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.455MRQ1.410+0.045
MRQ1.410TTM1.4100.000
TTM1.410YOY3.716-2.306
TTM1.4105Y7.303-5.892
5Y7.30310Y7.758-0.456
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.4551.931-0.476
MRQ1.4101.982-0.572
TTM1.4102.197-0.787
YOY3.7162.400+1.316
5Y7.3033.585+3.718
10Y7.7584.208+3.550
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Starpharma Holdings Ltd.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. All numbers in thousands.

Summary
Total Assets36,814
Total Liabilities8,698
Total Stockholder Equity28,116
 As reported
Total Liabilities 8,698
Total Stockholder Equity+ 28,116
Total Assets = 36,814

Assets

Total Assets36,814
Total Current Assets32,919
Long-term Assets3,895
Total Current Assets
Cash And Cash Equivalents 23,360
Net Receivables 6,340
Inventory 2,408
Other Current Assets 811
Total Current Assets  (as reported)32,919
Total Current Assets  (calculated)32,919
+/- 0
Long-term Assets
Property Plant Equipment 3,895
Long-term Assets  (as reported)3,895
Long-term Assets  (calculated)3,895
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities6,662
Long-term Liabilities2,036
Total Stockholder Equity28,116
Total Current Liabilities
Short-term Debt 1,571
Accounts payable 2,725
Other Current Liabilities 2,338
Total Current Liabilities  (as reported)6,662
Total Current Liabilities  (calculated)6,634
+/- 28
Long-term Liabilities
Long-term Liabilities  (as reported)2,036
Long-term Liabilities  (calculated)0
+/- 2,036
Total Stockholder Equity
Common Stock240,750
Retained Earnings -242,364
Accumulated Other Comprehensive Income 29,730
Total Stockholder Equity (as reported)28,116
Total Stockholder Equity (calculated)28,116
+/-0
Other
Cash and Short Term Investments 23,360
Common Stock Shares Outstanding 411,433
Current Deferred Revenue28
Liabilities and Stockholders Equity 36,814
Net Debt -19,832
Net Working Capital 26,257
Short Long Term Debt Total 3,528



5.2. Balance Sheets Structured

All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-301999-06-301998-06-30
> Total Assets 
0
0
29,053
26,025
18,859
10,715
18,491
12,500
25,013
30,423
24,653
28,847
37,567
29,807
54,268
48,550
36,862
44,383
59,039
66,591
58,511
48,859
39,078
73,238
66,175
52,086
36,814
36,81452,08666,17573,23839,07848,85958,51166,59159,03944,38336,86248,55054,26829,80737,56728,84724,65330,42325,01312,50018,49110,71518,85926,02529,05300
   > Total Current Assets 
0
0
28,936
25,789
17,838
8,459
16,242
8,354
17,108
11,408
9,255
13,176
24,230
19,941
44,865
39,332
28,598
35,080
50,276
65,678
57,453
47,809
36,676
70,755
60,658
47,122
32,919
32,91947,12260,65870,75536,67647,80957,45365,67850,27635,08028,59839,33244,86519,94124,23013,1769,25511,40817,1088,35416,2428,45917,83825,78928,93600
       Cash And Cash Equivalents 
0
0
28,079
25,412
17,434
7,892
15,658
8,166
14,284
10,073
7,482
11,595
22,851
18,918
42,812
33,840
24,028
30,848
45,972
61,188
51,319
41,251
30,054
60,500
49,918
35,180
23,360
23,36035,18049,91860,50030,05441,25151,31961,18845,97230,84824,02833,84042,81218,91822,85111,5957,48210,07314,2848,16615,6587,89217,43425,41228,07900
       Net Receivables 
0
0
698
305
252
420
471
43
2,824
1,335
1,773
1,481
1,323
870
1,917
5,314
4,211
3,866
3,938
3,838
5,911
959
6,087
8,439
7,836
8,235
6,340
6,3408,2357,8368,4396,0879595,9113,8383,9383,8664,2115,3141,9178701,3231,4811,7731,3352,8244347142025230569800
       Other Current Assets 
0
0
158
72
47
148
113
145
160
436
370
100
56
153
136
178
359
366
366
652
223
5,200
41
95
80
934
811
8119348095415,20022365236636635917813615356100370436160145113148477215800
   > Long-term Assets 
0
0
117
236
1,022
2,256
2,248
4,146
7,905
19,016
15,398
15,671
13,337
9,866
9,403
9,218
8,264
9,303
8,763
913
1,058
1,050
2,402
2,483
5,517
4,964
3,895
3,8954,9645,5172,4832,4021,0501,0589138,7639,3038,2649,2189,4039,86613,33715,67115,39819,0167,9054,1462,2482,2561,02223611700
       Property Plant Equipment 
0
0
117
236
948
2,005
1,556
1,233
1,431
1,111
758
447
219
280
414
411
509
910
690
913
1,058
1,050
2,402
2,483
5,517
4,964
3,895
3,8954,9645,5172,4832,4021,0501,0589136909105094114142802194477581,1111,4311,2331,5562,00594823611700
       Goodwill 
0
0
0
0
0
0
0
0
0
1,755
1,547
1,835
1,747
1,387
1,461
1,606
1,581
1,939
2,005
0
0
0
0
0
0
0
0
000000002,0051,9391,5811,6061,4611,3871,7471,8351,5471,755000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
4,087
16,031
13,093
13,389
11,371
8,199
7,528
7,201
6,174
6,454
6,068
0
0
0
0
0
0
0
0
000000006,0686,4546,1747,2017,5288,19911,37113,38913,09316,0314,08700000000
       Other Assets 
0
0
0
0
74
0
0
0
0
43
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000430000740000
> Total Liabilities 
0
0
199
1,110
1,593
1,472
898
2,534
3,697
4,699
4,270
3,348
2,723
2,114
5,617
2,582
3,911
6,825
9,615
5,607
5,234
6,464
7,752
10,938
17,782
17,271
8,698
8,69817,27117,78210,9387,7526,4645,2345,6079,6156,8253,9112,5825,6172,1142,7233,3484,2704,6993,6972,5348981,4721,5931,11019900
   > Total Current Liabilities 
0
0
199
1,110
1,593
1,269
755
2,365
3,033
3,260
3,715
3,143
2,665
2,041
5,435
2,459
3,844
6,769
9,575
5,521
5,164
6,426
6,697
10,429
10,231
14,473
6,662
6,66214,47310,23110,4296,6976,4265,1645,5219,5756,7693,8442,4595,4352,0412,6653,1433,7153,2603,0332,3657551,2691,5931,11019900
       Short-term Debt 
0
0
0
0
43
60
60
60
142
69
124
133
160
49
40
25
27
30
18
23
26
26
604
692
695
5,522
1,571
1,5715,52269569260426262318302725404916013312469142606060430000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
75
48
18
70
49
0
0
0
0
4,778
0
04,778000049701848750000000000000000
       Accounts payable 
0
0
160
1,044
1,208
721
446
1,647
1,898
1,855
1,623
1,764
1,346
940
4,156
1,208
2,586
5,481
8,210
4,034
3,023
4,098
4,394
6,711
6,762
6,615
2,725
2,7256,6156,7626,7114,3944,0983,0234,0348,2105,4812,5861,2084,1569401,3461,7641,6231,8551,8981,6474467211,2081,04416000
       Other Current Liabilities 
0
0
39
66
171
206
249
280
331
356
417
316
530
703
842
1,115
1,187
1,184
1,365
1,453
1,708
1,875
1,262
2,614
2,308
2,333
2,338
2,3382,3332,3082,6141,2621,8751,7081,4531,3651,1841,1871,115842703530316417356331280249206171663900
   > Long-term Liabilities 
0
0
0
0
0
204
144
169
664
1,440
555
205
58
73
182
123
67
56
40
86
70
38
1,055
509
7,551
2,798
2,036
2,0362,7987,5515091,05538708640566712318273582055551,44066416914420400000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18
0
47
23
0
970
475
7,494
2,750
0
02,7507,4944759700234701800000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
89
349
226
134
45
58
56
82
48
19
38
40
39
47
38
85
34
57
48
0
0485734853847394038194882565845134226349890000000
> Total Stockholder Equity
0
0
28,853
24,916
17,010
9,243
17,592
9,966
21,316
25,724
20,383
25,499
34,844
27,693
48,651
45,968
32,951
37,558
49,424
60,984
53,277
42,395
31,326
62,300
48,393
34,815
28,116
28,11634,81548,39362,30031,32642,39553,27760,98449,42437,55832,95145,96848,65127,69334,84425,49920,38325,72421,3169,96617,5929,24317,01024,91628,85300
   Common Stock
0
0
33,065
33,034
33,034
33,034
46,822
46,822
65,375
76,227
78,667
85,640
101,766
105,399
139,171
140,081
140,349
160,884
193,512
193,549
193,583
193,621
193,661
240,630
240,669
240,715
240,750
240,750240,715240,669240,630193,661193,621193,583193,549193,512160,884140,349140,081139,171105,399101,76685,64078,66776,22765,37546,82246,82233,03433,03433,03433,06500
   Retained Earnings Total Equity000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
-23
-86
-259
-47
13
-28
497
1,299
1,009
3,279
2,876
1,022
1,866
3,502
4,852
7,874
9,787
10,896
13,440
16,775
20,340
24,077
26,285
28,299
29,730
29,73028,29926,28524,07720,34016,77513,44010,8969,7877,8744,8523,5021,8661,0222,8763,2791,0091,299497-2813-47-259-86-2300
   Capital Surplus 000000000000000000000000000
   Treasury Stock000000000000000000000000000
   Other Stockholders Equity 
0
0
23
86
259
0
0
0
0
0
0
0
0
0
0
0
4,852
0
0
10,896
13,440
0
-10,986
-38,223
-22,108
-6,516
0
0-6,516-22,108-38,223-10,986013,44010,896004,85200000000000259862300



5.3. Balance Sheets

All numbers in thousands.